Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
440 participants
INTERVENTIONAL
2008-03-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa
NCT00138047
Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment.
NCT03421314
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection
NCT00000652
A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT
NCT00000653
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
NCT03408899
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zinc
zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children \< 12 mo)
Zinc
zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
Placebo
Zinc
zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zinc
zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
Severe acute malnutrition; Major congenital malformations
6 Weeks
60 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thrasher Research Fund
OTHER
Muhimbili University of Health and Allied Sciences
OTHER
Harvard School of Public Health (HSPH)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eduardo Villamor
Adjunct Associate Professor of International Nutrition
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eduardo Villamor, MD, DrPH
Role: PRINCIPAL_INVESTIGATOR
Harvard School of Public Health (HSPH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Muhimbili University College of Health Sciences
Dar es Salaam, , Tanzania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14511
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.